Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,345 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,345 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the sale, the insider now directly owns 159,796 shares of the company’s stock, valued at $2,341,011.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.30, for a total value of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.29, for a total value of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.28, for a total transaction of $47,353.80.

Hims & Hers Health Trading Down 5.4 %

NYSE HIMS opened at $13.65 on Friday. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74. The company has a market capitalization of $2.93 billion, a PE ratio of -1,365.00 and a beta of 1.05. The stock has a 50-day simple moving average of $18.36 and a 200 day simple moving average of $16.76.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same quarter last year, the firm earned ($0.03) EPS. Hims & Hers Health’s quarterly revenue was up 51.8% compared to the same quarter last year. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Jefferies Financial Group boosted their target price on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Piper Sandler reaffirmed a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a report on Tuesday, August 6th. Truist Financial boosted their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.29.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. Victory Capital Management Inc. lifted its stake in Hims & Hers Health by 23.0% in the fourth quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after buying an additional 3,429 shares in the last quarter. Diversify Advisory Services LLC bought a new position in Hims & Hers Health during the 1st quarter worth about $701,000. Forerunner Ventures Management LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $86,836,000. Sei Investments Co. lifted its holdings in shares of Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after purchasing an additional 37,890 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Hims & Hers Health by 3,444.9% during the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after buying an additional 208,621 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.